Chronic Fatigue Syndrome as a Delayed Reaction to Chronic Low-dose Organophosphate Exposure

References

• Fukuda K, Straus SE, Hickie I. and the International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–59
   PubMed Web of Science ®Google Scholar
• Bakheit AMO, Behan PO, Watson WS. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol Scand 1993; 87: 234–8
   PubMed Web of Science ®Google Scholar
• Bakheit AMO, Behan PO, Dinan TG. Possible upregulation of hypothalamic 5-hydroxy-tryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992; 304: 1010–2
   PubMed Web of Science ®Google Scholar
• Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorous insecticides. Lancet 1961; 24(June)1371–4
   Google Scholar
• Rosenstock L, Keifer M, Daniell W. Chronic central nervous system effects of acute organophos-phate pesticide intoxication. Lancet 1991; 338: 223–7
   PubMed Web of Science ®Google Scholar
• Sharp DS, Eskenazi B, Harrison R. Delayed health hazards of pesticide exposure. Ann Rev Publ Health 1986; 7: 441–71
   PubMed Web of Science ®Google Scholar
• Behan PO, Haniffah BAG. Chronic fatigue syndrome: a possible delayed hazard of pesticide exposure. Clin Infect Dis 1994; 18: S54, suppl. 1
   Google Scholar
• Murray VS, Wiseman HM, Dawling S. Health effects of organophosphate sheep dips. BMJ 1992; 305: 1090
   PubMedGoogle Scholar
• Newcombe DS. Immune surveillance, organophosphorous exposure and lymphomagenesis. Lancet 1992; 339: 539–41
   PubMed Web of Science ®Google Scholar
• Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. Cancer Res 1992; 52: 5485–8, suppl.
   PubMed Web of Science ®Google Scholar
• Wigle DT, Semenciw RM, Wilkins K. Mortality study of Canadian male farm operators: non-Hodgkin's lymphoma mortality and agricultural practices in Saskatchewan. J Natl Cancer Inst 1990; 7: 575–82
   Google Scholar
• Straus SE, Dale JK, Wright R. Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 1988; 81: 791–5
   PubMed Web of Science ®Google Scholar
• Morrison LJA, Behan WMH, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83: 441–6
   PubMed Web of Science ®Google Scholar
• Tirelli U, Marotta G, Improta S. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994; 40: 601–8
   PubMed Web of Science ®Google Scholar
• Landay AL, Jessop C, Lennette ET. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338: 707–12
   PubMed Web of Science ®Google Scholar
• Buchwald D, Cheney PR, Peterson DL. A chronic illness characterized by fatigue, neurological and immunologic disorders, and active human herpes virus type 6 infection. Ann Intem Med 1992; 166: 103–13
   Google Scholar
• Nakaya T, Takahash H, Nakamura Y. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome. FEBS Lett 1996; 378: 145–9
   PubMed Web of Science ®Google Scholar
• Gow JW, Behan WMH., dela Torre JC. Borna disease virus and chronic fatigue syndrome. Proceedings of First World Congress on Chronic Fatigue Syndrome and Related Disorders, Brussels, 1995
   Google Scholar
• Majeed T, Behan PO. Clinical overview of chronic fatigue syndrome. EOS. 1995; 8–14
   Google Scholar
• Charig EM, Anderson IM, Robinson JM. L-Tryptophan & prolactin release. Evidence for interaction between 5-HT1 & 5-HT2 receptors. Hum Psychol Pharmacol 1986; 1: 193–7
   Google Scholar
• Cleare AJ, Beam J, McGregor A. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Dis 1995; 34: 283–9
   PubMed Web of Science ®Google Scholar
• Janowsky DS, Davis JM. Psychological effects of cholinomimetic agents. Brain Acetylcholine and Neurophychiatric Disease. Plenum Press, New York 1979; 3–14
   Google Scholar
• Casaneuva FF, Belti R, Cella SG. Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. Acta Endocrinol 1983; 103: 15–20
   PubMedGoogle Scholar
• Majeed T. Neuroendocrine alteration in chronic fatigue syndrome. PhD thesis. Glasgow University. 1996
   Google Scholar
• Bowers MB, Boodman E, Sim VM. Some behavioural changes in man following anti-cholinesterase administration. J Nerv Men Dis 1964; 138: 383–9
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Istizuka T, Obara T. Dichotomic action of glucocorticoids on growth hormone secretion. Acta Endocrinol (Copenh) 1987; 116: 165–71
   PubMedGoogle Scholar
• Majeed T, Dinan TG, Thakore J. Defective dexamethasone induced growth hormone release in CFS: evidence of glucocorticoid receptor resistance and lack of plasticity?. J Irish Coll Phys & Surg 1995; 24: 20–24
   Google Scholar
• Blisard KS, Kornfeld M, McFeeley P. The investigation of alleged insecticide toxicity: a case involving chlordane exposure, multiple sclerosis and peripheral neuropathy. J Forensic Sci 1986; 31: 1499–504
   PubMed Web of Science ®Google Scholar
• Krupp LB, Alvarez LA, LaRocca NG. Fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435–7
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Appenzeller O. Amantadine, fatigue and multiple sclerosis. Arch Neurol 1988; 45: 1104–6
   PubMed Web of Science ®Google Scholar